Orthofix Names Julie Dewey Chief Investor Relations and Communications Officer; Max Reinhardt Begins as President of Global Spine

LEWISVILLE, Texas, June 11, 2024 – (BUSINESS WIRE)- Orthofix Medical Inc. (NASDAQ:OFIX), a number one world spine and orthopedics firm, immediately introduced the appointment of Julie Dewey as Chief Investor Relations and Communications Officer. Moreover, as beforehand introduced, Max Reinhardt begins as President of the corporate’s world spine enterprise. Dewey and Reinhardt will serve on Orthofix’s Government Management Workforce.

A seasoned investor relations and communications government, Dewey beforehand held roles as a company officer for a number of world publicly traded medical machine firms. Most not too long ago, she served as Chief Communications and Investor Relations Officer for Treace Medical Ideas, Inc., a medical expertise firm centered on the surgical administration of bunion and associated midfoot deformities. Earlier in her profession, she was the Senior Vice President and Chief Communications Officer at Wright Medical Group, a world medical machine firm centered on extremities and biologics that was acquired by Stryker in 2020.

“We’re excited to welcome Julie to the corporate,” mentioned Orthofix President and Chief Government Officer Massimo Calafiore. “She is deeply revered inside the trade and brings along with her huge data of our markets, applied sciences, and progress methods. Her appointment not solely strengthens our government management staff, but it surely additionally additional establishes our give attention to increasing our outreach with buyers and analysts as we proceed to drive profitability and progress for our shareholders.”

Dewey is thought for her sturdy give attention to transformative IR program improvement, efficiently positioning medical expertise firms within the monetary market, and increasing outreach and engagement with the funding group.

“I’m thrilled to affix Orthofix on this new management position at such a transformational time in its progress trajectory,” mentioned Dewey. “I look ahead to working with Massimo and the remainder of the Orthofix staff to execute on the corporate’s progress technique and ship a best-in-class expertise for the funding group and key stakeholders.”

About Julie Dewey

Julie Dewey has greater than 25 years of expertise in investor relations, company communications and advertising management roles at a number of medical expertise firms. Dewey served as Chief Communications and Investor Relations Officer at Treace Medical Ideas, Inc. Previous to Treace, Dewey was Chief Company Communications and IR Officer at Nevro Corp. Earlier than becoming a member of Nevro, she was Senior Vice President and Chief Communications Officer at Wright Medical Group, N.V., a number one orthopaedic firm centered on extremities and biologics that was acquired by Stryker in 2020. Earlier in her profession, Dewey held investor relations and advertising positions at high medical expertise firms together with ev3 Inc. (acquired by Covidien), Kyphon Inc. (acquired by Medtronic) and Thoratec Company (acquired by St. Jude Medical/Abbott).

Dewey holds a BS in Enterprise Administration from the College of Southern California and a Grasp of Enterprise Administration diploma from Pepperdine College. Dewey is a Fellow of the Nationwide Investor Relations Institute (NIRI), the skilled affiliation of company officers and investor relations consultants answerable for communication amongst company administration, shareholders, securities analysts and different monetary group constituents. Dewey additionally holds the Investor Relations Constitution (IRC) credential.

As an inducement to enter into employment with Orthofix, Dewey was granted (i) performance-based vesting restricted inventory models that settle into 61,444 shares of frequent inventory at goal achievement, (ii) time-based vesting restricted inventory models that settle into 30,722 shares of frequent inventory, and (iii) inventory choices to buy 70,620 shares of frequent inventory. The performance-based vesting restricted inventory models vest on the finish of a three-year efficiency interval based mostly on the Firm’s whole stockholder return relative to an trade peer group index throughout such interval, whereas the time-based vesting restricted inventory models vest in equal tranches over three years. The inventory choices vest upon achievement of each service- and performance-based standards, whichever is the later of (a) the date sure service-based situations are met (which will likely be met over three years) and (b) the date that the typical closing worth of the Firm’s frequent inventory over a one-month calendar interval has been equal to or nice than 150% of the closing worth of the Firm’s frequent inventory on the grant date. The grants, which had been accepted by Orthofix’s Board of Administrators, had been made below standalone inducement award agreements accepted pursuant to NASDAQ Market Rule 5635(c)(4).

Max Reinhardt Begins as President of World Backbone

Max Reinhardt has stepped into the position of President of World Backbone the place he’ll lead the corporate’s spine and biologics enterprise.

As an inducement to enter into employment with Orthofix, Reinhardt was granted (i) performance-based vesting restricted inventory models that settle into 28,802 shares of frequent inventory at goal achievement, (ii) time-based vesting restricted inventory models that settle into 14,401 shares of frequent inventory, and (iii) inventory choices to buy 190,731 shares of frequent inventory. The performance-based vesting restricted inventory models vest on the finish of a three-year efficiency interval based mostly on the Firm’s whole stockholder return relative to an trade peer group index throughout such interval, whereas the time-based vesting restricted inventory models vest in equal tranches over three years. In regard to the inventory choices, 33,103 of the inventory choices vest upon achievement of each service- and performance-based standards, whichever is the later of (a) the date sure service-based situations are met (which will likely be met over three years) and (b) the date that the typical closing worth of the Firm’s frequent inventory over a one-month calendar interval has been equal to or nice than 150% of the closing worth of the Firm’s frequent inventory on the grant date. The remaining 157,628 inventory choices vest on the third anniversary of the grant date. The grants, which had been accepted by Orthofix’s Board of Administrators, had been made below standalone inducement award agreements accepted pursuant to NASDAQ Market Rule 5635(c)(4).

About Orthofix

Orthofix is a number one world spine and orthopedics firm with a complete portfolio of biologics, progressive spinal {hardware}, bone progress therapies, specialised orthopedic options, and a number one surgical navigation system. Its merchandise are distributed in additional than 60 international locations worldwide.

The Firm is headquartered in Lewisville, Texas, the place it conducts basic enterprise, product improvement, medical schooling and manufacturing, and has major places of work in Carlsbad, CA, with a give attention to spine and biologics product innovation and surgeon schooling, and Verona, Italy, with an emphasis on product innovation, manufacturing, and medical schooling for orthopedics. The mixed Firm’s world R&D, industrial and manufacturing footprint additionally consists of services and places of work in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Maidenhead, UK, Munich, Germany, Paris, France and São Paulo, Brazil.

Ahead-Wanting Statements

This information launch could embrace forward-looking statements inside the that means of Part 21E of the Securities Change Act of 1934, as amended, and Part 27A of the Securities Act of 1933, as amended. In some circumstances, you’ll be able to determine forward-looking statements by terminology akin to “could,” “will,” “ought to,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “tasks,” “intends,” “predicts,” “potential,” “proceed” or different comparable terminology. Orthofix cautions you that statements included on this information launch that aren’t an outline of historic information are forward-looking statements which are based mostly on the Firm’s present expectations and assumptions. Every forward-looking assertion contained on this information launch is topic to dangers and uncertainties that would trigger precise outcomes to vary materially from these expressed or implied by such assertion. Relevant dangers and uncertainties embrace, amongst others: the flexibility of newly launched merchandise to carry out as designed and meant and to satisfy the wants of surgeons and sufferers, together with on account of the dearth of sturdy medical validation; and the dangers recognized below the heading “Threat Components” in Orthofix Medical Inc.’s Annual Report on Kind 10-Ok for the fiscal 12 months ended December 31, 2023, which was filed with the Securities and Change Fee (SEC) on March 5, 2024. The Firm’s public filings with the Securities and Change Fee can be found at www.sec.gov. You’re cautioned to not place undue reliance on forward-looking statements, which communicate solely as of the date when made. Orthofix doesn’t intend to revise or replace any forward-looking assertion set forth on this information launch to replicate occasions or circumstances arising after the date hereof, besides as could also be required by regulation.